Zhejiang Ausun Pharmaceutical Co., Ltd. (603229) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Ausun Pharmaceutical Co., Ltd.

Why is Zhejiang Ausun Pharmaceutical Co., Ltd. ?

Negative results in Sep 25

NET SALES(Q) At CNY 164.09 MM has Fallen at -16.2%
NET PROFIT(HY) At CNY 88.54 MM has Grown at -23.85%
ROCE(HY) Lowest at 7.96%

With ROE of 7.84%, it has a expensive valuation with a 3.44 Price to Book Value

Over the past year, while the stock has generated a return of 6.92%, its profits have fallen by -32.1%

Underperformed the market in the last 1 year

The stock has generated a return of 6.92% in the last 1 year, much lower than market (China Shanghai Composite) returns of 22.49%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zhejiang Ausun Pharmaceutical Co., Ltd. for you?

Medium Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Zhejiang Ausun Pharmaceutical Co., Ltd.

-7.86%

0.65

33.33%

China Shanghai Composite

20.18%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

10.90%

EBIT Growth (5y)

-4.03%

EBIT to Interest (avg)

62.16

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.28

Sales to Capital Employed (avg)

0.29

Tax Ratio

13.53%

Dividend Payout Ratio

40.58%

Pledged Shares

Institutional Holding

ROCE (avg)

16.62%

ROE (avg)

11.06%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.20

EV to EBIT

62.04

EV to EBITDA

41.28

EV to Capital Employed

3.89

EV to Sales

8.80

PEG Ratio

Dividend Yield

1.10%

ROCE (Latest)

6.26%

ROE (Latest)

4.73%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

PRE-TAX PROFIT(Q)

At CNY 110.37 MM has Grown at 218.99%

NET PROFIT(Q)

At CNY 99.4 MM has Grown at 203.23%

RAW MATERIAL COST(Y)

Fallen by -4.44% (YoY

CASH AND EQV(HY)

Highest at CNY 2,380.11 MM

NET SALES(Q)

Highest at CNY 308.67 MM

-26What is not working for the Company

NET PROFIT(HY)

At CNY 23.47 MM has Grown at -74.22%

OPERATING CASH FLOW(Y)

Lowest at CNY 114.49 MM

ROCE(HY)

Lowest at 4.56%

DEBT-EQUITY RATIO (HY)

Highest at -23.94 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.42 times

INTEREST(Q)

Highest at CNY 2.83 MM

Here's what is working for Zhejiang Ausun Pharmaceutical Co., Ltd.

Net Sales

At CNY 308.67 MM has Grown at 56.04%

over average net sales of the previous four periods of CNY 197.81 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 110.37 MM has Grown at 218.99%

over average net sales of the previous four periods of CNY 34.6 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 99.4 MM has Grown at 203.23%

over average net sales of the previous four periods of CNY 32.78 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales

Highest at CNY 308.67 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Cash and Eqv

Highest at CNY 2,380.11 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -4.44% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Ausun Pharmaceutical Co., Ltd.

Operating Cash Flow

Lowest at CNY 114.49 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 2.83 MM has Grown at 14.41%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest

Highest at CNY 2.83 MM

in the last five periods and Increased by 14.41% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -23.94 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 2.42 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio